- What is Chronic immunotoxicity of immune checkpoint inhibitors?
- This anti-aging medicine has gone astray: Chronic inflammation leads to a decrease in NAD+
- FDA Approved Treatment Funded by Ice Bucket Challenge Donors
- Similar to HIV: Another deadly monkey virus may spread to humans
- 2022 Nobel Prize Winner Paper: The risk of severe COVID-19 is inherited from Neanderthals
- Breakthrough method ‘starves’ highly lethal cancer tumors and eradicates them
The Lancet: Develop a new type of CAR-T cell therapy for multiple myeloma!
Lancet: Develop a new type of CAR-T cell therapy for multiple myeloma! CAR-T cell therapy, namely chimeric antigen receptor T cell therapy, is a new technology developed by scientists in recent years for precise targeted therapy of tumor cells.
Recently, an article was published in the international journal The Lancet entitled “Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/ In the 2 open-label study” research report, scientists from the Sarah Cannon Institute in the United States and other institutions have developed a new CAR-T therapy for the treatment of multiple myeloma through research.
Photomicrograph of plasmacytoma, which is histologically related to multiple myeloma.
Image source: Wikipedia/CC BY-SA 3.0
According to Yi Lin, MD, CAR-T cell therapy is a special type of immunotherapy, which mainly involves engineering the host’s T cells to identify and destroy cancer cells, thereby using the patient’s own immunity to achieve cancer treatment. The FDA approved the first CAR-T cell therapy for the treatment of multiple myeloma—Abecma (idecabtagene vicleucel) in March of this year. Now researchers are exploring another CAR-T cell therapy for the treatment of multiple myeloma.
The researchers stated that the CARTITUDE-1 research plan is a registration phase 1B/II clinical trial. In the trial, the researchers tested the B-cell mature antigen-targeted CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel). The therapy is suitable for patients with multiple myeloma who have previously received at least three first-line standard drug treatments, including proteasome inhibitors, immunomodulatory drugs, and CD38 antibodies.
Cilta-cel is modified by the patient’s own T cells, which are genetically modified and infused into the patient in a single dose. The researchers found that the overall response rate of the therapy was 97%, while the complete response rate and progression-free survival rate were 67% and 77%, respectively, and the overall survival rate was 89%.
Image source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00933-8/fulltext
Researcher Lin said that recently we also introduced the latest developments of this research at the American Clinical Oncology Annual Meeting. We said at the annual meeting that the response of patients receiving this therapy will continue to deepen, with a complete response rate of 80%. , And for myeloma patients who have undergone multiple treatments, these results are very impressive.
In the later period, researchers will continue to study and understand the clinical characteristics of patients with long-lasting remissions obtained using this therapy, as well as the reasons behind the relapse of some patients and improvement measures.
Although it cannot be compared in two independent single-arm studies of ide-cel and cilta-cel, the impressively higher response rate and progression-free survival of patients receiving cilta-cel is very exciting . However, the possibility of transforming this research into a clinically individualized therapy may require solving a variety of underlying problems, including ensuring that the transition from manufacturing to commercial products used for research is reliable.
In summary, the results of this article show that a single infusion of cilta-cel at the target dose of 0.75*10 6th power/kg CAR-positive living T cells may enable a large number of pretreated multiple myeloma patients to obtain early, deep and Long-lasting response and controllable safety, and current research results also form the basis for the recent submission of regulatory documents.
(source:internet, reference only)